Vildium Inhalation Capsule

Introduction

Vilanterol Trifenatate and Umeclidinium Bromide are two medications commonly used in combination to manage chronic obstructive pulmonary disease (COPD) and asthma. Vilanterol is a long-acting beta-agonist (LABA), while Umeclidinium is a long-acting muscarinic antagonist (LAMA). This combination aims to provide extended bronchodilation and improve respiratory function.

Uses

The combination of Vilanterol Trifenatate and Umeclidinium Bromide is used for the maintenance treatment of COPD and asthma. It helps to improve lung function, reduce symptoms, and decrease the frequency of exacerbations. It is not intended for the relief of acute bronchospasm but is used for long-term management of respiratory conditions.

Mechanism of Action

Vilanterol Trifenatate works by stimulating beta-2 adrenergic receptors in the smooth muscle of the airways, leading to relaxation and bronchodilation. Umeclidinium Bromide acts as an antagonist of muscarinic receptors, which also results in bronchodilation by inhibiting acetylcholine-induced constriction of airway smooth muscle. The combined action of these drugs provides prolonged bronchodilation and improved airflow.

How Long Does It Take to Work?

Vilanterol Trifenatate and Umeclidinium Bromide typically begin to show effects within 15-30 minutes of inhalation. The maximum benefit is usually seen within a few hours, with sustained effects over 24 hours, making it suitable for once-daily dosing.

Absorption

Both medications are administered via inhalation, which allows them to act locally in the lungs. Systemic absorption is minimal, but the drugs are still absorbed into the bloodstream to some extent. The inhalation route ensures that the medications are delivered directly to the site of action, reducing systemic side effects.

Route of Elimination

The primary route of elimination for both Vilanterol and Umeclidinium is through the urine. Both drugs are metabolized in the liver, with metabolites excreted primarily in the urine.

Dosage

The standard dosage for the combination inhaler is typically one inhalation of 1 vial (umeclidinium 62.5 mcg / vilanterol 25 mcg) once daily. Dosage may vary based on individual patient needs and physician recommendations.

Administration

Vilanterol Trifenatate and Umeclidinium Bromide are administered via a dry powder inhaler. Patients should follow specific instructions for the correct use of the inhaler to ensure proper dosage and efficacy. It is essential to use the inhaler consistently at the same time each day.

Side Effects

Common side effects may include:

• Dry mouth
• Throat irritation
• Headache
• Increased cough
• Sinusitis

• Rapid heartbeat
• Palpitations
• Increased blood pressure
• Severe allergic reactions

Toxicity

Toxicity can occur with overdoses, leading to:

• Severe cardiovascular effects such as tachycardia and arrhythmias
• Significant increases in blood pressure
• Severe respiratory effects like paradoxical bronchospasm

Precautions

Precautions include:

• Use with caution in patients with a history of cardiovascular disease, hypertension, or hyperthyroidism.
• Monitor for potential adverse effects on glucose metabolism and potassium levels.
• Avoid using with other LABAs or LAMAs to prevent additive effects and potential overdose.

Interaction

Interactions to be aware of include:

• Beta-blockers may reduce the effectiveness of Vilanterol and should be used cautiously.
• Other anticholinergic medications may have additive effects with Umeclidinium, increasing the risk of side effects.

Disease Interaction

Considerations for disease interactions:

• Patients with pre-existing cardiac conditions or hypertension should be monitored closely.
• Caution in patients with glaucoma or urinary retention conditions due to anticholinergic effects of Umeclidinium.

Drug Interaction

Drug interactions include:

• Concomitant use with other inhaled bronchodilators should be carefully monitored to avoid excessive bronchodilation.
• Interactions with CYP3A4 inhibitors (e.g., ketoconazole) may increase the levels of Vilanterol.

Food Interactions

Food interactions are generally minimal; however, patients should avoid grapefruit and grapefruit juice as they may affect the metabolism of medications metabolized by CYP3A4, including Vilanterol.

Pregnancy Use

The safety of Vilanterol Trifenatate and Umeclidinium Bromide during pregnancy has not been well established. Use during pregnancy should be considered only if the potential benefit justifies the potential risk to the fetus. Always consult with a healthcare provider before use during pregnancy.

Lactation Use

The excretion of Vilanterol and Umeclidinium in breast milk is unknown. Caution should be exercised when administering these medications to breastfeeding women. Consult with a healthcare provider to weigh the potential benefits and risks.

Acute Overdose

In the event of an acute overdose, symptoms may include:

• Severe tachycardia
• Increased blood pressure
• Severe chest pain
• Paradoxical bronchospasm

Contraindication

Contraindications include:

• Hypersensitivity to Vilanterol, Umeclidinium, or any component of the inhaler.
• Patients with a history of severe allergic reactions to similar medications.

Use Direction

Patients should use the inhaler exactly as prescribed by their healthcare provider. It is important to follow the instructions for proper inhalation technique and not to exceed the recommended dose. Regular use at the same time each day is advised for optimal control of symptoms.

Storage Conditions

Store the inhaler at room temperature, away from heat and moisture. Keep it tightly closed and out of reach of children. Do not freeze or expose the inhaler to extreme temperatures.

Volume of Distribution

The volume of distribution for Vilanterol and Umeclidinium is not specifically defined in terms of pharmacokinetics due to their primarily local effects in the lungs when inhaled.

Half Life

The half-lives of these medications are:

• Vilanterol: Approximately 12 hours.
• Umeclidinium: Approximately 11 hours.

Clearance

Both medications are primarily cleared through renal excretion of their metabolites. The systemic clearance rates are designed to maintain therapeutic levels while minimizing the risk of accumulation.